#enhertu number 2
#HER2low

Check out Dr. Shanu Modi MSK Department of Medicine discussing #ESMO23 'DESTINY-Breast04 Updated Survival Results - T-DXd vs. Tx of Physician’s Choice in pts With HER2-Low Unresectable and/or Met. Breast Cancer'

#bcsm #breastcancer #HER2low
Full video on #VuMedi
👇
bit.ly/DB04ESMO23

So honoured and excited to get to meet Paolo Tarantino in person!! Thank you so much for all the inspirations!

#ASCO23
#bcsm
#HER2low

#GI23
Dr. Van Laarhoven gave a nice overview of other, non-IO🎯💊for #Gastriccancer
➡️Claudin 18.2 - including newer treatments like CAR-T
➡️FGFR - including a novel FGFR2b specific mAb
➡️HER2 - including targeting HER2low disease
➡️TME

Very exciting times!

Check out Dr. Hope Rugo Hope Rugo UCSF Helen Diller Family Comprehensive Cancer Ctr & Dr. Sara Tolaney Sara Tolaney Dana-Farber’s Breast Oncology Center panel discussion on #ESMO23 Metastatic Breast Cancer updates and their impact on clinical practice

#bcsm #breastcancer #mBC #TNBC #HER2low
Full video on #VuMedi
👇
bit.ly/mBCESMO23

Incidence of brain metastases in 17,000 pts with MBC per subtype.

1) Incidence increases per line, except HR-, HER2+ which is early event
2) HER2Low, no impact on BM incidence.

Multidisciplinary discussion on Mirrors of Medicine clinical cases:

What treatment after 1st line TNBC, Her2low BC?

Liron Pantanowitz and Mustafa Yousif propose Quantitative Image Analysis (QIA) to address difficulties with #her2low in breast cancer cases. API - pathbytes Liron Pantanowitz Michigan Pathology

🚨Thrilled to share our latest article on treatment options of #HER2low #breastcancer & proposed treatment sequencing algorithm published in American Cancer Society journal ACS Journal Cancer. Shipra Gandhi Ruth O'Regan ajay dhakal Roswell Park Roswell Park Hematology/Oncology Fellowship
acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

Don't miss Dr. Tarantino Paolo Tarantino discussing the impact of #HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for #MetastaticBreastCancer in today's Poster Spotlight Discussion on #AntibodyDrugConjugates . #SABCS23 #TDXd #Her2Low #DanaFarberSABCS23

Para perfilar un poco la población con #her2low para trastuzumab deruxtecan: EPAR pág 49, criterios de inclusión del ensayo pivotal (no viene en el New England del DESTINY-Breast04). ema.europa.eu/en/documents/v…

Turno del Dr. Manuel Alva: Manuel Alva Bianchi Nos da su visión de cómo tratar los tumores HER2-low.
'Por suerte tenemos dos ADCs: Saci Govitecan y Trastu Deruxtecan'.

#9AbrilMamaCentro #CancerdeMamaMetastasico #HER2low #ADCs

¿Estás al tanto de la importancia de la evaluación correcta del HER2? Cobra especial relevancia diagnosticar los #HER2low de cara a los nuevos tratamientos. ¡Únete al minicurso HER2 en cáncer de mama!
ℹ️: campusvirtual.seaponline.es
Director: Vicente Peg, MD, PhD

Happy to lead the joint effort from Yale Cancer Center YaleBreastCancer and Foundation Medicine to better characterize genomic alterations from tumors from >2k patients with breast cancer subtypes stratified by ER and HER2 statuses #HER2low #bcsm SABCS Maryam Lustberg MD MPH Smilow Cancer Hospital

A big thank you to Dr. Fernando Aldaco and the Oncology Mexican Society for inviting me to discuss the role of #TDXd and #SacituzumabGovitecan in #HER2low #breastcancer and #TDXd in neoadjuvant/first-line disease.
Very interesting debates with great colleagues from LATAM and USA

Excellent presentation showing activity of TDXd in small group of HER2Low Leptomeningeal disease! SABCS

¿Y si es un tumor #HER2low progresado?

Como ponente el Dr. Manuel Alva Manuel Alva Bianchi del Hospital 12 Octubre y como moderadora la Dra. Isabel Echavarria Isabel Echavarria del #HospitalGregorioMarañon se centrarán en este supuesto en relación al uso de #quimioterapia

#9AbrilMamaCentro

Dr. Modi presents updated #DB04 results with #TDXd in #HER2low

▫️Median f/u 32.0 mo

▫️ OS HR 0.69, 17.6 to 23.9 mo for HR+,

▫️PFS HR 0.36 , 4.2 to 9.6 mo for HR+,

▫️TNBC OS 8.3 to 17.1 mo, PFS 2.9 to 6.3 mo...smaller # though

#ESMO23 #bcsm

#HER2 is getting far more than just #BreastCancer
Are we witnessing a breakthrough in treating #HER2 #brain #metastases with novel antibody drug conjugates like #Enhertu ??
The whole story of #Enhertu #ADCs #HER2 incl #HER2 low #HER2 ultralow is getting far more interesting 👆…

First up TDXd aka Enhertu, a ADC approved for both HER2+ and HER2low MBC. Pretty sure it was approved in HER2low population about a year ago due to results from DESTINY-breast02 trial. #SABCS23